Form 4: Corcept Therapeutics Executive Sean Maduck Executes Stock Option and Sells Shares Under 10b5-1 Plan

Sean Maduck, President of Corcept Endocrinology, exercised stock options and sold 50,000 shares of Corcept Therapeutics (CORT) common stock at $28 per share on May 13, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• On May 13, 2024, Sean Maduck, President of Corcept Endocrinology at Corcept Therapeutics, exercised stock options to acquire 50,000 shares of common stock at a price of $3.88 per share.
• Simultaneously, Maduck sold 50,000 shares of Corcept Therapeutics common stock at $28 per share.
• These transactions were executed under a pre-arranged 10b5-1 trading plan.
• Following these transactions, Maduck directly owns 85,222 shares of Corcept Therapeutics common stock.
• Maduck also indirectly owns 10,000 shares through Duckhill Capital, LLC and another 10,000 shares through the Sean and Molly Maduck Living Trust.
• The filing also notes that Maduck holds 41,986 derivative securities in the form of stock options.

Sentiment

Score: 6

Explanation: Neutral sentiment. The transactions are part of a pre-arranged plan, and while the sale could be perceived negatively, the continued holdings and option exercises suggest ongoing confidence.

Positives

• The exercise of stock options and subsequent sale indicates Maduck's belief in the company's long-term value, as he initially acquired the shares.

Negatives

• The sale of 50,000 shares could be perceived negatively by investors, although it was conducted under a pre-arranged 10b5-1 trading plan.

Risks

• Executive stock sales, even under 10b5-1 plans, can sometimes create short-term price volatility.

Future Outlook

The document does not contain specific forward-looking statements, but the executive's continued holdings suggest ongoing involvement with the company.

Industry Context

Executive stock transactions are common in the pharmaceutical industry and are often scrutinized by investors for insights into company performance and management confidence. The use of a 10b5-1 plan indicates a pre-arranged strategy to avoid accusations of insider trading.

Comparison to Industry Standards

• Executive compensation practices, including stock options and restricted stock awards, are standard across the pharmaceutical industry.
• Companies like Gilead Sciences, Amgen, and Biogen also utilize similar compensation structures to incentivize their executives.
• The execution of trades under 10b5-1 plans is a common practice among executives to manage their stock holdings while complying with insider trading regulations.

Stakeholder Impact

• The stock sale could have a minor impact on shareholder sentiment, but the pre-arranged nature of the transaction mitigates potential concerns.

Key Dates